SCHEMBL119177

SCHEMBL119177

O=S(=O)(Nc1ncc(C(F)(F)F)cc1Cl)c1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.77
MEN1 O00255 5/20 0.77
TDP1 Q9NUW8 1/20 0.77
HTT P42858 5/20 0.70
LMNA P02545 4/20 0.70
POLB P06746 4/20 0.70
MAPT P10636 4/20 0.61
ALDH1A1 P00352 4/20 0.61
SMN1; SMN2 Q16637 2/20 0.60
NPSR1 Q6W5P4 2/20 0.60
XBP1 P17861 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.51
AHR P35869 1/20 0.51
TRPM8 Q7Z2W7 1/20 0.51
PTGES2 Q9H7Z7 1/20 0.51
MDM2 Q00987 1/20 0.48
KDM4E B2RXH2 2/20 0.48
GAA P10253 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27866035 0.87 MEN1 (1.00) KMT2AMEN1TDP1HTTLMNA
SCHEMBL20104469 0.85 HTT (0.80) KMT2AMEN1TDP1HTTLMNA
SCHEMBL119695 0.81 MEN1 (0.71) KMT2AMEN1TDP1HTTLMNA
SCHEMBL119713 0.81 MEN1 (0.61) KMT2AMEN1TDP1HTTLMNA
SCHEMBL29967706 0.80 KMT2A (0.54) KMT2AMEN1TDP1HTTLMNA
SCHEMBL29023889 0.80 KMT2A (0.54) KMT2AMEN1TDP1HTTLMNA
SCHEMBL30834821 0.77 MEN1 (0.64) KMT2AMEN1TDP1HTTLMNA
SCHEMBL27182849 0.77 MEN1 (0.60) KMT2AMEN1TDP1HTTLMNA
SCHEMBL3476966 0.77 PPARG (0.54) KMT2AMEN1TDP1HTTLMNA
SCHEMBL18307327 0.77 KMT2A (0.49) KMT2AMEN1TDP1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102427810-A Sulfamoylbenzoic acid derivatives as TRPM8 antagonists RAQUALIA PHARMA INC 2012-04-25 CN disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 KMT2A 941/4885MEN1 1593/4885TDP1 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.